OncoSec Medical Incorporated – Chapter 7 Proceeding

Case No. 23-15178 (CMG)

Filed in the United States Bankruptcy Court for the District of New Jersey

Click here for Notice of Commencement of Case

Click here for Notice of Public Sale of Assets

Notice to File Proofs of Claim will be provided when it is available

Designed to Arm the Immune System to Fight Cancer

We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer.

Clinical Pipeline

Our core technology platform continues to advance through clinical trials for various cancers

Learn More


Our plasmid DNA delivery platform is designed to boost the body’s immune system to target and attack cancer

Learn More


We have a track record of establishing, operating and evolving high-performance partnerships globally

Learn More